| Target Molecule | Semaglutide |
| Synonyms | Semaglutide (free base); NNC 0113-0217; NN9535; OG217SC |
| CAS Number | 910463-68-2 |
| Peptide Backbone | [Aib8, Arg34]-GLP-1(7-37); 31-residue chain |
| Sequence (3-Letter) | H-His-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys(acyl)-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly-OH |
| Side-Chain Modification | Lys26 acylated with a γ-Glu spacer, two AEEA (OEG) units, and a C18 fatty diacid (octadecanedioic acid) |
| Molecular Formula | C₁₈₇H₂₉₁N₄₅O₅₉ |
| Molecular Weight | 4113.6 |
| Service Category | Custom Peptide Synthesis / CDMO Manufacturing |
| Synthesis Purity | Customizable (e.g., ≥98%, ≥99% via HPLC) |
| Appearance | White to off-white lyophilized powder |
| Counter Ion | Acetate (customizable content) or sodium salt options |
| Synthesis Technology | Solid-Phase Peptide Synthesis (SPPS) and targeted side-chain conjugation |
| Modification Options | Complex lipidation, PEGylation, targeted impurity standards synthesis |
| Available Scale | Milligram (R&D) to Kilogram (Commercial CDMO) |
| Analytical Data | COA, HPLC, MS, and extended regulatory documentation provided per batch |
| Usage | Raw material synthesized strictly for laboratory research, analytical development, and industrial formulation. Not a finished medicine. |
Semaglutide (CAS 910463-68-2) is a highly modified 31-residue GLP-1 receptor agonist. We target this complex sequence to provide high-purity reference standards and raw materials for pharmaceutical research and analytical development.
We utilize optimized solid-phase peptide synthesis (SPPS) techniques. This approach ensures precise amino acid coupling, specifically managing the steric hindrance of the Aib substitution at position 8, yielding highly pure materials that meet rigorous pharmaceutical specifications.
Yes. The pharmacokinetic profile of Semaglutide relies on a complex side chain at Lys26. We utilize targeted modification techniques to execute this precise lipidation and PEGylation via strict orthogonal protection strategies. We also intentionally synthesize specific degradation products to serve as reference standards for stability-indicating assays.
Our infrastructure scales production from milligram-level analytical batches to kilogram-level commercial manufacturing. We optimize liquid-phase handling and large-scale preparative HPLC to maintain consistent impurity profiles across all production volumes, specifically managing the strong self-associating properties of this lipophilic peptide.
We operate as a technical partner offering complete peptide CDMO solutions. Our team manages sequence optimization, impurity profiling, analytical method validation, and regulatory documentation to support complex drug development pipelines.
Semaglutide (CAS 910463-68-2) is an advanced, acylated analogue of human glucagon-like peptide-1 (GLP-1). Synpeptide provides comprehensive synthetic solutions for this molecule. The structural challenges of this sequence, including the Aib substitution and complex lipid side chain, demonstrate our advanced capabilities in pharmaceutical peptide manufacturing and analytical development.
Constructing a 31-amino acid chain with unnatural amino acid substitutions requires exact control over coupling efficiency. Our custom peptide synthesis platform utilizes optimized Solid-Phase Peptide Synthesis (SPPS) protocols to overcome steric hindrance at the Aib8 position. This systematic approach ensures high-fidelity assembly, consistently delivering raw materials with stringent purity profiles (typically ≥98% via HPLC) for advanced research.
The structural complexity of Semaglutide is defined by its acylation at Lys26, incorporating a γ-glutamate spacer, two AEEA (OEG) units, and a C18 fatty diacid. Through our peptide modification services, we execute these multi-step conjugations with strict orthogonal protection strategies to prevent cross-reactions. We also synthesize defined degradation variants on demand, providing essential impurity reference standards for researchers validating analytical methods.
Transitioning highly lipophilic, self-associating peptides from analytical scale to commercial volumes presents significant engineering challenges. We execute large-scale peptide synthesis for Semaglutide by optimizing liquid-phase handling and high-capacity preparative HPLC purification. This infrastructure guarantees a stable supply chain, scaling from milligram research quantities to kilogram commercial batches with exact lot-to-lot reproducibility.
We provide structural engineering and manufacturing capacity as a fully integrated peptide CDMO. Our technical teams support pharmaceutical developers through process optimization, rigorous stability assessments, and complete analytical documentation. We deliver the precise data and scalable manufacturing required to advance complex peptide APIs through the development lifecycle.
